|
CN1747747B
(zh)
|
2003-01-06 |
2012-09-05 |
安吉奥开米公司 |
作为穿过血脑屏障的载体的抑酶肽及类似物
|
|
EP2476756A1
(en)
*
|
2005-06-15 |
2012-07-18 |
Massachusetts Institute of Technology |
Amine-containing lipids and uses thereof
|
|
US9365634B2
(en)
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
RU2518240C2
(ru)
|
2008-04-18 |
2014-06-10 |
Ангиочем Инк. |
Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
|
|
US8921314B2
(en)
|
2008-10-15 |
2014-12-30 |
Angiochem, Inc. |
Conjugates of GLP-1 agonists and uses thereof
|
|
RU2531591C2
(ru)
|
2008-10-15 |
2014-10-20 |
Ангиокем Инк. |
Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
|
|
MX2011004859A
(es)
|
2008-11-07 |
2011-08-03 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
|
MX2011005963A
(es)
|
2008-12-05 |
2011-09-01 |
Angiochem Inc |
Conjugados de neurotensina o analogos de neurotensina y sus usos.
|
|
CN102300987A
(zh)
|
2008-12-17 |
2011-12-28 |
安吉奥开米公司 |
膜型-1基质金属蛋白抑制剂及其用途
|
|
AU2010239069B2
(en)
|
2009-04-20 |
2015-05-14 |
Angiochem Inc |
Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
|
|
MX2012000016A
(es)
|
2009-07-02 |
2012-03-26 |
Angiochem Inc |
Conjugados de peptidos multimericos y sus usos.
|
|
PL3338765T3
(pl)
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9193827B2
(en)
|
2010-08-26 |
2015-11-24 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
US9238716B2
(en)
|
2011-03-28 |
2016-01-19 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
DK3336082T3
(da)
|
2011-06-08 |
2020-04-27 |
Translate Bio Inc |
Spaltelige lipider
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
KR20150000461A
(ko)
|
2011-10-27 |
2015-01-02 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
EP2882706A1
(en)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Amine-containing lipidoids and uses thereof
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
ES2882110T3
(es)
|
2013-03-14 |
2021-12-01 |
Translate Bio Inc |
Métodos y composiciones para administrar anticuerpos codificados con ARNm
|
|
ES2981185T3
(es)
|
2013-03-14 |
2024-10-07 |
Translate Bio Inc |
Métodos para la purificación de ARN mensajero
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP2968586B1
(en)
|
2013-03-14 |
2018-07-25 |
Translate Bio, Inc. |
Cftr mrna compositions and related methods and uses
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2014179562A1
(en)
|
2013-05-01 |
2014-11-06 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
US11224642B2
(en)
*
|
2013-10-22 |
2022-01-18 |
Translate Bio, Inc. |
MRNA therapy for argininosuccinate synthetase deficiency
|
|
WO2015061467A1
(en)
*
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Lipid formulations for delivery of messenger rna
|
|
CA2928040A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
|
MX2016005239A
(es)
*
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
|
|
JP6822841B2
(ja)
|
2014-03-09 |
2021-01-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
オルニチントランスカルバミラーゼ（ｏｔｃ）欠損症の処置において有用な組成物
|
|
JP6372118B2
(ja)
*
|
2014-03-18 |
2018-08-15 |
東洋インキＳｃホールディングス株式会社 |
両性界面活性剤とその製造方法
|
|
PT3122878T
(pt)
*
|
2014-03-24 |
2019-02-01 |
Translate Bio Inc |
Terapia de arnm para o tratamento de doenças oculares
|
|
DK3134131T3
(en)
|
2014-04-23 |
2022-02-07 |
Modernatx Inc |
Nucleic acid vaccines
|
|
JP6571679B2
(ja)
|
2014-04-25 |
2019-09-04 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの精製方法
|
|
US10022455B2
(en)
|
2014-05-30 |
2018-07-17 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
WO2015191693A2
(en)
*
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
CA2952824C
(en)
*
|
2014-06-24 |
2023-02-21 |
Shire Human Genetic Therapies, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
CA2953265C
(en)
|
2014-07-02 |
2023-09-26 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
WO2016025643A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Brush-poly(glycoamidoamine)-lipids and uses thereof
|
|
MA56412A
(fr)
|
2014-12-05 |
2022-05-04 |
Translate Bio Inc |
Thérapie par l'arn messager pour le traitement des maladies articulaires
|
|
WO2016149508A1
(en)
|
2015-03-19 |
2016-09-22 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for pompe disease
|
|
WO2016187531A1
(en)
*
|
2015-05-21 |
2016-11-24 |
Ohio State Innovation Foundation |
Benzene-1,3,5-tricarboxamide derivatives and uses thereof
|
|
US10980892B2
(en)
|
2015-06-15 |
2021-04-20 |
Angiochem Inc. |
Methods for the treatment of leptomeningeal carcinomatosis
|
|
ES2949540T3
(es)
*
|
2015-06-19 |
2023-09-29 |
Massachusetts Inst Technology |
2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
AU2016342048B2
(en)
|
2015-10-22 |
2022-09-08 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3365009A4
(en)
|
2015-10-22 |
2019-07-03 |
ModernaTX, Inc. |
VACCINES AGAINST HERPES SIMPLEX VIRUS
|
|
TN2018000154A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Respiratory syncytial virus vaccine
|
|
WO2017112943A1
(en)
|
2015-12-23 |
2017-06-29 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
KR102369898B1
(ko)
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
|
JP7088911B2
(ja)
|
2016-05-18 |
2022-06-21 |
モデルナティエックス インコーポレイテッド |
リラキシンをコードするポリヌクレオチド
|
|
HRP20220479T1
(hr)
|
2016-06-01 |
2022-05-27 |
Athira Pharma, Inc. |
Spojevi
|
|
CN109312313A
(zh)
|
2016-06-13 |
2019-02-05 |
川斯勒佰尔公司 |
用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
|
|
IL265109B2
(en)
|
2016-09-13 |
2024-05-01 |
Allergan Inc |
Stabilized non-protein clostridial toxin compositions
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
JP7560946B2
(ja)
|
2016-11-10 |
2024-10-03 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの皮下送達
|
|
MA46762A
(fr)
|
2016-11-10 |
2019-09-18 |
Translate Bio Inc |
Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm
|
|
EP3808380A1
(en)
|
2016-12-08 |
2021-04-21 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
ES2925083T3
(es)
|
2017-02-27 |
2022-10-13 |
Translate Bio Inc |
Métodos de purificación de ARN mensajero
|
|
CA3054321A1
(en)
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
AU2018224326B2
(en)
|
2017-02-27 |
2024-01-04 |
Translate Bio, Inc. |
Novel codon-optimized CFTR mRNA
|
|
WO2018165257A1
(en)
|
2017-03-07 |
2018-09-13 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
|
WO2018170270A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
ES2981244T3
(es)
*
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
US10278957B2
(en)
|
2017-09-11 |
2019-05-07 |
Protagonist Therapeutics, Inc. |
Opioid agonist peptides and uses thereof
|
|
EP3461487A1
(en)
*
|
2017-09-29 |
2019-04-03 |
Nlife Therapeutics S.L. |
Compositions and methods for the delivery of mrna to hepatic cells
|
|
TW202423453A
(zh)
*
|
2017-10-17 |
2024-06-16 |
美商薩羅塔治療公司 |
用於反義遞送之細胞穿透肽
|
|
EP3700537A4
(en)
*
|
2017-10-17 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
BICYCLIC PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
|
|
WO2019090359A1
(en)
|
2017-11-06 |
2019-05-09 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
CN110997919B
(zh)
|
2017-12-01 |
2024-04-02 |
苏州瑞博生物技术股份有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
US11660347B2
(en)
|
2017-12-01 |
2023-05-30 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
|
|
CN118236391A
(zh)
|
2017-12-01 |
2024-06-25 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7261494B2
(ja)
|
2017-12-01 |
2023-04-20 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
KR102128951B1
(ko)
*
|
2017-12-21 |
2020-07-01 |
탑월드(주) |
비즈왁스와 동식물성 오일을 함유하는 화장료 조성물
|
|
CN110959011B
(zh)
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
WO2019152802A1
(en)
|
2018-02-02 |
2019-08-08 |
Translate Bio, Inc. |
Cationic polymers
|
|
CN108467475B
(zh)
*
|
2018-03-08 |
2020-02-14 |
山西大学 |
一种环状聚合物及其制备方法和应用
|
|
TW202002990A
(zh)
|
2018-03-16 |
2020-01-16 |
美商薩羅塔治療公司 |
用於反義遞送之嵌合肽
|
|
AU2019271132B2
(en)
|
2018-05-15 |
2026-02-05 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger RNA
|
|
US11964051B2
(en)
|
2018-05-16 |
2024-04-23 |
Translate Bio, Inc. |
Ribose cationic lipids
|
|
AU2019275068B2
(en)
|
2018-05-24 |
2024-09-26 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
WO2019232095A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
AU2019277361B2
(en)
|
2018-05-30 |
2025-04-24 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
AU2019277355A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
US11547666B2
(en)
|
2018-05-30 |
2023-01-10 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
CN108727209A
(zh)
*
|
2018-06-20 |
2018-11-02 |
复旦大学 |
具有n，n-二烷基亮氨酸结构的化合物及其制备方法
|
|
WO2019246386A1
(en)
|
2018-06-21 |
2019-12-26 |
Ra Pharmaceuticals Inc. |
Cyclic polypeptides for pcsk9 inhibition
|
|
EP3810177B1
(en)
|
2018-06-21 |
2024-12-04 |
Ra Pharmaceuticals, Inc. |
Cyclic polypeptides for pcsk9 inhibition
|
|
US11505575B2
(en)
|
2018-06-21 |
2022-11-22 |
Merck Sharp & Dohme Llc |
Cyclic polypeptides for PCSK9 inhibition
|
|
WO2019246352A1
(en)
|
2018-06-21 |
2019-12-26 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist bicyclo-compounds
|
|
IL321719A
(en)
|
2018-06-21 |
2025-08-01 |
Merck Sharp ַ& Dohme Llc |
Pcsk9 antagonist compounds
|
|
US11530244B2
(en)
|
2018-06-21 |
2022-12-20 |
Merck Sharp & Dohme Llc |
Cyclic polypeptides for PCSK9 inhibition
|
|
KR20210056331A
(ko)
|
2018-07-23 |
2021-05-18 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 건조 분말 제형
|
|
US20210317461A1
(en)
|
2018-08-09 |
2021-10-14 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
EP3842534A4
(en)
|
2018-08-21 |
2022-07-06 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
|
|
CN118421617A
(zh)
|
2018-08-24 |
2024-08-02 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
|
KR20210091120A
(ko)
|
2018-08-29 |
2021-07-21 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
|
|
WO2020047467A2
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
|
US12564645B2
(en)
|
2018-09-14 |
2026-03-03 |
Translate Bio, Inc. |
Methods for treatment of methylmalonic acidemia
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
EP3862024A4
(en)
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
KR20210090634A
(ko)
|
2018-10-19 |
2021-07-20 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 무펌프 캡슐화
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
EP3877538A1
(en)
|
2018-11-08 |
2021-09-15 |
Translate Bio, Inc. |
Methods and compositions for messenger rna purification
|
|
AU2019374871B2
(en)
|
2018-11-09 |
2025-09-11 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
WO2020097376A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
KR102860605B1
(ko)
*
|
2018-11-09 |
2025-09-15 |
트랜슬레이트 바이오 인코포레이티드 |
에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진
|
|
AU2019378763B2
(en)
|
2018-11-12 |
2025-06-26 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
EP3883592A1
(en)
|
2018-11-21 |
2021-09-29 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
CN113453707A
(zh)
|
2018-12-21 |
2021-09-28 |
库瑞瓦格股份公司 |
用于疟疾疫苗的rna
|
|
CN112423794A
(zh)
|
2018-12-28 |
2021-02-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113412273B
(zh)
|
2019-01-07 |
2025-08-22 |
川斯勒佰尔公司 |
用于治疗原发性纤毛运动障碍的组合物和方法
|
|
EP4491229A3
(en)
|
2019-02-08 |
2025-05-14 |
CureVac SE |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
US12453759B2
(en)
|
2019-05-03 |
2025-10-28 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
EP3968952A1
(en)
|
2019-05-14 |
2022-03-23 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
CN113811613B
(zh)
|
2019-05-22 |
2024-04-05 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
JP7663951B2
(ja)
|
2019-05-22 |
2025-04-17 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
WO2020238766A1
(zh)
|
2019-05-24 |
2020-12-03 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
WO2020243540A1
(en)
|
2019-05-31 |
2020-12-03 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
AU2020297606B2
(en)
|
2019-06-21 |
2026-04-02 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
ES2992127T3
(es)
|
2019-07-08 |
2024-12-09 |
Translate Bio Inc |
Nanopartículas lipídicas cargadas de ARNm mejoradas y sus procesos de fabricación
|
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
WO2021016430A1
(en)
|
2019-07-23 |
2021-01-28 |
Translate Bio, Inc. |
Stable compositions of mrna-loaded lipid nanoparticles and processes of making
|
|
JP7600208B2
(ja)
|
2019-07-29 |
2024-12-16 |
ジョージア テック リサーチ コーポレイション |
拘束された脂質を含むナノ材料およびその使用
|
|
EP4003397B1
(en)
|
2019-07-30 |
2025-02-26 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
JP2022544412A
(ja)
|
2019-08-14 |
2022-10-18 |
キュアバック アーゲー |
免疫賦活特性が減少したｒｎａ組み合わせおよび組成物
|
|
WO2021041770A1
(en)
|
2019-08-30 |
2021-03-04 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
|
JP7650873B2
(ja)
|
2019-10-09 |
2025-03-25 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの組成物、方法および使用
|
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
JP7306252B2
(ja)
*
|
2019-12-13 |
2023-07-11 |
東洋インキＳｃホールディングス株式会社 |
紐状ミセル組成物および含水ゲル
|
|
US12577259B2
(en)
|
2019-12-20 |
2026-03-17 |
Merck Sharp & Dohme Llc |
PCSK9 antagonist compounds
|
|
KR20220142432A
(ko)
|
2019-12-20 |
2022-10-21 |
트랜슬레이트 바이오 인코포레이티드 |
메신저 rna의 직장 전달
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
US12053551B2
(en)
|
2019-12-20 |
2024-08-06 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
WO2021141969A1
(en)
|
2020-01-09 |
2021-07-15 |
Guide Therapeutics, Inc. |
Nanomaterials
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
WO2021173840A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
|
CA3173567A1
(en)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
|
WO2021178396A1
(en)
*
|
2020-03-02 |
2021-09-10 |
Trustees Of Tufts College |
Imidazole-based synthetic lipidoids for in vivo mrna delivery into immune cells
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
CN115348873B
(zh)
*
|
2020-03-26 |
2025-04-29 |
北京脑科学与类脑研究中心 |
氨基酸介导的基因递送及其用途
|
|
EP4146680A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
WO2021226436A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
US12605399B2
(en)
|
2020-05-07 |
2026-04-21 |
Translate Bio, Inc. |
Compositions for CFTR MRNA therapy
|
|
US12514932B2
(en)
|
2020-05-14 |
2026-01-06 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
EP4149425A1
(en)
|
2020-05-15 |
2023-03-22 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
TW202206097A
(zh)
|
2020-05-20 |
2022-02-16 |
美商旗艦先鋒創新有限責任公司 |
冠狀病毒抗原組成物及其用途
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
CN111517974A
(zh)
*
|
2020-05-28 |
2020-08-11 |
浙江昂拓莱司生物技术有限公司 |
一种氨基酸n端烷基化衍生物及其制备方法和应用
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
|
EP4208196A1
(en)
|
2020-09-03 |
2023-07-12 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
EP4213882A4
(en)
|
2020-09-15 |
2025-02-26 |
Verve Therapeutics, Inc. |
LIPID FORMULATIONS FOR GENE EDITING
|
|
WO2022076562A1
(en)
|
2020-10-06 |
2022-04-14 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
US20220110884A1
(en)
|
2020-10-12 |
2022-04-14 |
Translate Bio, Inc. |
Process of preparing mrna-loaded lipid nanoparticles
|
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
|
AU2021373892A1
(en)
|
2020-11-09 |
2023-07-06 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
|
CN116723829A
(zh)
|
2020-11-25 |
2023-09-08 |
翻译生物公司 |
稳定的液体脂质纳米颗粒配制品
|
|
US11932705B2
(en)
|
2020-12-18 |
2024-03-19 |
Merck Sharp & Dohme Llc |
Cyclic polypeptides for PCSK9 inhibition
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
BR112023012377A2
(pt)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
Composições de trems modificadas e usos das mesmas
|
|
JP2024504614A
(ja)
|
2021-01-14 |
2024-02-01 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡがコードする抗体を送達する方法および組成物
|
|
US12059477B2
(en)
|
2021-01-20 |
2024-08-13 |
Beam Therapeutics Inc. |
Nanomaterials
|
|
CA3203784A1
(en)
*
|
2021-01-20 |
2022-07-28 |
Beam Therapeutics Inc. |
Ionizable lipids for nanomaterials
|
|
MX2023008328A
(es)
|
2021-01-20 |
2023-08-15 |
Beam Therapeutics Inc |
Nanomateriales que comprenden una caracteristica biodegradable.
|
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
CN117157101A
(zh)
|
2021-02-08 |
2023-12-01 |
德克萨斯大学系统董事会 |
不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法
|
|
EP4291201A4
(en)
*
|
2021-02-10 |
2025-04-16 |
ElevateBio Technologies, Inc. |
Compounds, compositions, and methods of using thereof
|
|
KR20230175196A
(ko)
|
2021-03-23 |
2023-12-29 |
리코드 테라퓨틱스, 인크. |
폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법
|
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
|
MX2023011400A
(es)
|
2021-03-26 |
2023-10-09 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogenicas.
|
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
WO2022225918A1
(en)
|
2021-04-19 |
2022-10-27 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
WO2022264109A1
(en)
|
2021-06-18 |
2022-12-22 |
Sanofi |
Multivalent influenza vaccines
|
|
JP2024527541A
(ja)
|
2021-07-01 |
2024-07-25 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａの送達のための組成物
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CN117940158A
(zh)
|
2021-09-03 |
2024-04-26 |
库瑞瓦格欧洲公司 |
用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
|
|
DK4271818T3
(da)
|
2021-09-17 |
2024-11-04 |
Flagship Pioneering Innovations Vi Llc |
Sammensætninger og fremgangsmåder til fremstilling af cirkulære polyribonukleotider
|
|
CA3234107A1
(en)
|
2021-10-05 |
2023-04-13 |
Florent PERAL |
Methods for freezing and freeze-drying lipid nanoparticles (lnps) and lnps obtained with the same
|
|
WO2023059806A1
(en)
|
2021-10-06 |
2023-04-13 |
Massachusetts Institute Of Technology |
Lipid nanoparticles for drug delivery to microglia in the brain
|
|
US20240417714A1
(en)
|
2021-10-18 |
2024-12-19 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
EP4419081A1
(en)
|
2021-10-22 |
2024-08-28 |
Sail Biomedicines, Inc. |
Mrna vaccine composition
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
TW202346593A
(zh)
|
2021-11-05 |
2023-12-01 |
法商賽諾菲公司 |
呼吸道融合病毒rna疫苗
|
|
AU2022388747A1
(en)
|
2021-11-10 |
2024-06-20 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
KR20240107356A
(ko)
|
2021-11-23 |
2024-07-09 |
세일 바이오메디슨스, 인크. |
박테리아-유래 지질 조성물 및 이의 용도
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
CA3238370A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
CA3239417A1
(en)
|
2021-11-30 |
2023-06-08 |
Yvonne CHAN |
Human metapneumovirus vaccines
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CN119095613A
(zh)
|
2021-12-17 |
2024-12-06 |
赛诺菲 |
莱姆病rna疫苗
|
|
MX2024007307A
(es)
|
2021-12-17 |
2024-08-06 |
Flagship Pioneering Innovations Vi Llc |
Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes.
|
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
AU2022417517A1
(en)
|
2021-12-22 |
2024-06-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
MX2024007870A
(es)
|
2021-12-23 |
2024-08-15 |
Flagship Pioneering Innovations Vi Llc |
Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
|
|
US20250099392A1
(en)
*
|
2022-01-20 |
2025-03-27 |
Ohio State Innovation Foundation |
Compositions comprising lipid compounds and methods of making and use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
GB202202297D0
(en)
|
2022-02-21 |
2022-04-06 |
Verona Pharma Plc |
Formulation production process
|
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
EP4499607A1
(en)
|
2022-03-25 |
2025-02-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CN119325466A
(zh)
*
|
2022-04-08 |
2025-01-17 |
尚威天成信使核糖核酸治疗公司 |
可电离脂质化合物和脂质纳米颗粒组合物
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
CN119522105A
(zh)
|
2022-05-06 |
2025-02-25 |
赛诺菲 |
核酸疫苗的信号序列
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
雙股ｄｎａ組合物及相關方法
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
CN120737001A
(zh)
*
|
2022-06-02 |
2025-10-03 |
厦门赛诺邦格生物科技股份有限公司 |
一种氨基酸阳离子脂质
|
|
CN117460711B
(zh)
*
|
2022-06-02 |
2025-07-08 |
厦门赛诺邦格生物科技股份有限公司 |
一种含有不饱和键的氨基酸阳离子脂质
|
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CN119487048A
(zh)
|
2022-06-30 |
2025-02-18 |
赛诺菲 |
作为选择性il-23受体拮抗剂的新型肽
|
|
AU2023311822A1
(en)
|
2022-07-20 |
2025-01-09 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
AU2023320333A1
(en)
|
2022-08-01 |
2025-01-16 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
|
WO2024028492A1
(en)
|
2022-08-04 |
2024-02-08 |
Sanofi |
Quantitative assessment of rna encapsulation
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
EP4577236A1
(en)
|
2022-08-22 |
2025-07-02 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Vaccines against coronaviruses
|
|
EP4581012A2
(en)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2023374764A1
(en)
|
2022-11-04 |
2025-06-19 |
Sanofi Pasteur Inc. |
Respiratory syncytial virus rna vaccination
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
EP4622630A1
(en)
|
2022-11-21 |
2025-10-01 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
EP4630057A1
(en)
|
2022-12-08 |
2025-10-15 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
|
WO2024126809A1
(en)
|
2022-12-15 |
2024-06-20 |
Sanofi |
Mrna encoding influenza virus-like particle
|
|
EP4637813A1
(en)
|
2022-12-20 |
2025-10-29 |
Sanofi Pasteur |
Rhinovirus mrna vaccine
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
KR20250153793A
(ko)
|
2023-01-27 |
2025-10-27 |
세일 바이오메디슨스, 인크. |
변형된 지질 조성물 및 이의 용도
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
EP4665736A2
(en)
|
2023-02-13 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
AU2024222598A1
(en)
|
2023-02-17 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
JP2026507514A
(ja)
|
2023-02-17 |
2026-03-04 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
修飾されたシトシンを含むｄｎａ組成物
|
|
WO2024177424A1
(ko)
*
|
2023-02-24 |
2024-08-29 |
에스티팜 주식회사 |
신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자
|
|
JP2026504797A
(ja)
|
2023-03-02 |
2026-02-10 |
サノフィ・パスツール |
クラミジア（Ｃｈｌａｍｙｄｉａ）の治療に使用するための組成物
|
|
JP2026509258A
(ja)
|
2023-03-08 |
2026-03-17 |
キュアバック エスイー |
核酸送達のための新規な脂質ナノ粒子製剤
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
AU2024235803A1
(en)
|
2023-03-15 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
JP2026514004A
(ja)
|
2023-04-12 |
2026-05-01 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
修飾されたｔｒｅｍ、組成物及びその関連方法
|
|
EP4695391A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Trems for use in correction of missense mutations
|
|
MX2025012337A
(es)
|
2023-04-17 |
2026-02-03 |
Sanofi Pasteur Inc |
Formulaciones de polvo seco reconstituibles y métodos de uso de las mismas
|
|
EP4698150A1
(en)
|
2023-04-19 |
2026-02-25 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024231727A1
(en)
|
2023-05-05 |
2024-11-14 |
Sanofi |
Compositions for use in treatment of acne
|
|
TW202508620A
(zh)
|
2023-05-10 |
2025-03-01 |
尼可拉斯 克拉克 |
呼吸道mrna組合疫苗
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
CN121620357A
(zh)
|
2023-06-01 |
2026-03-06 |
赛诺菲巴斯德有限公司 |
包含mRNA脂质纳米颗粒的热稳定组合物
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
CN121620356A
(zh)
|
2023-06-26 |
2026-03-06 |
维罗纳制药公司 |
包含恩塞芬汀的颗粒组合物
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
EP4734960A1
(en)
|
2023-06-28 |
2026-05-06 |
Sanofi Pasteur Inc. |
Sterol analogs in lipid nanoparticle formulations
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
WO2025010554A1
(en)
*
|
2023-07-07 |
2025-01-16 |
Yoltech Therapeutics Co., Ltd. |
Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
|
|
CN121889496A
(zh)
|
2023-07-19 |
2026-04-17 |
赛诺菲 |
牙龈卟啉单胞菌抗原构建体
|
|
US20250092426A1
(en)
|
2023-07-25 |
2025-03-20 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
CN122055354A
(zh)
*
|
2023-09-01 |
2026-05-15 |
波西达治疗公司 |
类脂质化合物及相关组合物和用途
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025051975A1
(en)
|
2023-09-06 |
2025-03-13 |
Sanofi |
Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
CN121909205A
(zh)
|
2023-09-08 |
2026-04-21 |
赛诺菲 |
作为选择性il-23受体抑制剂的新型肽
|
|
WO2025051920A1
(en)
|
2023-09-08 |
2025-03-13 |
Sanofi |
New peptides as selective il-23 receptor inhibitors
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025090023A1
(en)
*
|
2023-10-24 |
2025-05-01 |
Agency For Science, Technology And Research |
A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound, and related methods thereof
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
US12553042B2
(en)
|
2023-12-01 |
2026-02-17 |
Recode Therapeutics, Inc. |
Method for quantifying an amount of capped messenger RNA
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
CN118852328A
(zh)
*
|
2024-07-02 |
2024-10-29 |
北京大学 |
肽基可离子化脂质合成及其应用
|
|
WO2026027730A1
(en)
|
2024-07-31 |
2026-02-05 |
Sanofi |
Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026033123A1
(en)
|
2024-08-08 |
2026-02-12 |
Sanofi Pasteur Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
WO2026037656A1
(en)
|
2024-08-13 |
2026-02-19 |
Basf Se |
Reaction products of amino acids with monooxirane compounds for corrosion inhibition
|
|
CN118652301B
(zh)
*
|
2024-08-19 |
2024-12-13 |
仁景(苏州)生物科技有限公司 |
药物递送系统
|
|
WO2026053147A1
(en)
|
2024-09-05 |
2026-03-12 |
Sanofi Pasteur Inc. |
Helper lipids and lnp compositions comprising same
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026052773A1
(en)
|
2024-09-06 |
2026-03-12 |
Sanofi |
Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|